Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study
Abdulrahman Majrashi, Ying X. Gue, Alena Shantsila, Stella Williams, Gregory Y. H. Lip, Andrew R. Pettitt · 2024
Read Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study by Abdulrahman Majrashi, Ying X. Gue, Alena Shantsila, Stella Williams, Gregory Y. H. Lip, Andrew R. Pettitt (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641840.txt.
Description
Ibrutinib transformed treatment for chronic lymphocytic leukemia, but it strains the heart. Abdulrahman Majrashi and co-authors compared its cardiac risks with an older chemotherapy combination in real-world records. They matched patients on a large health database so the two groups started alike.
Death rates did not differ between the groups. The ibrutinib group, though, developed atrial fibrillation at nearly twice the rate and high blood pressure somewhat more often. Heart failure, dangerous rhythms, and bleeding were similar. The authors note that newer drugs in the same class are gentler on the heart. They urge cardio-oncology planning for leukemia patients with heart risks.
Catalog record
| CREATOR | Abdulrahman Majrashi, Ying X. Gue, Alena Shantsila, Stella Williams, Gregory Y. H. Lip, Andrew R. Pettitt |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |